Sutro Biopharma (STRO) Preferred Stock Liabilities (2016 - 2018)

Sutro Biopharma has disclosed Preferred Stock Liabilities across 3 years of filings, most recently posting $187.2 million for Q3 2018.

• Preferred Stock Liabilities for Q3 2018 came in at $187.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2018 was $187.2 million (changed N/A YoY), and the FY2017 annual result was $102.5 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities came in at $187.2 million for Q3 2018 at Sutro Biopharma, up from $102.5 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $187.2 million in Q3 2018 to a low of $102.5 million in Q4 2016.
• The 3-year median for Preferred Stock Liabilities is $102.5 million (2016), against an average of $130.8 million.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2017, while the deepest fall reached 0.0% in 2017.
• Sutro Biopharma's Preferred Stock Liabilities stood at $102.5 million in 2016, then changed by 0.0% to $102.5 million in 2017, then jumped by 82.67% to $187.2 million in 2018.
• The last three Preferred Stock Liabilities figures came in at $187.2 million (Q3 2018), $102.5 million (Q4 2017), and $102.5 million (Q4 2016), per Business Quant data.